Skip to content

The Role of Breast Milk Neutrophils From Mothers With Metabolic Diseases After Nutritional Intervention. Impact on Infant Development and Response to Pulmonary Infections

The Role of Breast Milk Neutrophils From Mothers With Metabolic Diseases and Impact on Infant Development and Response to Pulmonary Infections

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06833554
Acronym
PI2222/01813
Enrollment
80
Registered
2025-02-18
Start date
2023-01-01
Completion date
2025-12-31
Last updated
2025-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes Mellitus (GDM)

Brief summary

This project aims at identifying variations in breast milk neutrophils among lactating mothers with gestational diabetes or obesity (objective 1), and to describe how a dietary intervention with Omega-3 fatty acids affects these changes (objective 2). The occurrence of respiratory infections on the progeny will be analysed, as well as its development and the impact on gut microbiota and epigenetic changes (objective 3). The involvement of breast milk on the neonate's microbiota (sub-objective 1) and epigenetic variations (sub-objective 2) will be depicted. In addition, the direct engagement of milk neutrophils in the ability of the progeny to react against lung infections will be studied (sub-objective 3). To attain these mother milk and blood samples will be obtained from three groups of lactating mothers: control, obesity or gestational diabetes, upon a dietary intervention with Omega-3 fatty acids. Neutrophil populations of maternal blood and milk samples will be studied by flow cytometry and in vitro assays. The microbiome and miRNA content of infant's saliva and tool samples will be characterized by 16s rRNA gene sequencing and PCR. The occurrence of respiratory infections and the development the infants participating in the study will be tracked during the first 2 years of life by telephone surveys. To study the impact of the presented maternal variables on the progeny upon a respiratory inflammation on a systemic level, mouse models will be employed. The offspring of lactating dams with gestational diabetes or obesity will be subjected to an artificial acute lung infection. The progression of the lung disease will be studied by histology and the neutrophil profile in the organs of the litter by flow cytometry. The response to acute lung injury after fecal transplantation with infant's microbiota intro germ-free mice as well as of wild type pups breastfeed by neutropenic dams will complement the animal studies.

Interventions

Dietary supplementation with Omega-3 Fatty Acids to study the effect on the immune system of breast milk

DIETARY_SUPPLEMENTPlacebo

Inert dietary supplement, without activity in the activation of the immune system of breast milk

Sponsors

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* full term pregnancy (\>37 weeks) * mother age 18-50 years * intention to practice exclusive breastfeeding for at least 3 months

Exclusion criteria

* preterm pregnancy (\<37 weeks) * multiple delivery * delivery complications that compromise the well-being of the newborn * congenital abnormalities of the baby * pathologies of the mother such as hypertension, HELLP syndrome, thyroids alterations or nephropathies - drugs or alcohol abuse record * occurrence of mastitis during the study * mothers practicing tandem nursing

Design outcomes

Primary

MeasureTime frame
Characterization of milk neutrophils from three groups of lactating mothers: control or gestational diabetes.From enrollment to end of treatment at 3 months
Characterization of microbiota and miRNA content of breast milkFrom enrollment to end of treatment at 3 months

Countries

Spain

Contacts

Primary ContactAlmudena Ortega-Gomez
almudena.ortega@ibima.eu+34 952367600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026